Cannabis and neurodevelopment: implications for psychiatric disorders
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The developing brain is susceptible to the effects of exogenous cannabinoids both during the perinatal period through maternal cannabis use and in young adolescent users. Emerging data from human and animal perinatal exposure studies demonstrate a subtle rather than gross effect of cannabis upon later functioning including; specific cognitive deficits especially in visuospatial function; impulsivity, inattention and hyperactivity; depressive symptoms; and substance use disorders. From animal studies motor control systems, neuroendocrine function and nociception may additionally be affected. Fetal studies indicate that these outcomes may be through cannabinoid mediated influences on the ontogeny of, especially dopamine and opioid, neurotransmitter systems. The effect of cannabinoids in the adolescent suggest long‐term deleterious outcomes in cognition, depressive symptoms, schizophrenia and substance use disorders. Much of these data support a neurodevelopmental effect, however, predisposing genetic and/or environmental factors cannot be excluded from human studies. Gender specific differences have been observed in both human and animal studies implying sex hormone and related factors may interact with cannabinoids in neurodevelopment. Further understanding how cannabinoids influence neurodevelopment will inform public debate about the health effects of cannabis but also open avenues in discerning how modulation of the endocannabinoid system may assist in the development of therapeutic tools for a variety of neuropsychiatric disorders. Copyright © 2006 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 3×
“Subsequently a number of other molecules, all derivatives of long chain polyunsaturated fatty acids, have been proposed as putative ligands, however, currently it would seem that anandamide and 2-arachidonylglcerol, 2-AG, are the predominant CNS endocannabinoids (Piomelli, 2003).”
BackgroundInfluentialImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 1×
“CB1 receptors in the cortex, hippocampus and amygdala are predominantly located on the axon terminals of the cholecystokinin-8-positive subclass of GABA interneurons (Tsou et al., 1998, 1999).”
BackgroundIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399 · cited 3×
“However, more recently a small but clear signal has emerged from studies identifying cannabis use as a causative factor in a small proportion of schizophrenia cases (Arseneault et al., 2002; Zammit et al., 2002).”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090 · cited 2×
“Through Gi/o the CB1 receptor inhibits adenylate cyclase, however, in addition, its other signalling effects include stimulating mitogen activated protein kinases, closing Ca2þ channels and opening Kþ channels (Di Marzo et al., 2004).”
BackgroundGlass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052 · cited 1×
“The CB1 receptor is widely distributed throughout the brain with highest densities in the hippocampus, basal ganglia and cerebellum, moderate densities in the cerebral cortex and nucleus accumbens and low densities in the hypothalamus and brain stem (Glass et al., 1997; Westlake et al., 1994).”
BackgroundCannabis use and mental health in young people: cohort study.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., & Hall, W. (2002) · BMJ · doi:10.1136/bmj.325.7374.1195 · Cited by 997
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871 · cited 2×
“However, more recently a small but clear signal has emerged from studies identifying cannabis use as a causative factor in a small proportion of schizophrenia cases (Arseneault et al., 2002; Zammit et al., 2002).”
BackgroundEffects of Maternal Marijuana and Cocaine Use on Fetal Growth
Zuckerman, B., Frank, D. A., Hingson, R., Amaro, H., Levenson, S. M., Kayne, H., Parker, S., Vinci, R., Aboagye, K., Fried, L. E., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903233201203 · Cited by 852
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608
New evidence for neurotransmitter influences on brain development
Levitt, P., Harvey, J. A., Friedman, E., Simansky, K., & Murphy, E. H. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01028-4 · Cited by 362 · cited 1×
“The dopaminergic system plays a neurodevelopmental role in addition to neurotransmission (Levitt et al., 1997; Spencer et al., 1998) implying that cannabis induced changes in this system may result in both structural and functional consequences.”
BackgroundFried, P. A., Watkinson, B., & Gray, R. (1998) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(97)00091-3 · Cited by 235 · cited 6×
“Importantly these findings, especially deficits involving visual memory and analysis, persisted in the OPPS cohort as 13–16 year olds and contrasted with those found for nicotine exposure only (Fried et al., 2003).”
BackgroundInfluentialFried, P. A., & Makin, J. E. (1987) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(87)90062-6 · Cited by 212 · cited 1×
“Data do not support an association between cannabis use and increased prematurity, miscarriage or physical abnormality rates (Day et al., 1991; Fried et al., 1983), however, heightened autonomic arousal in neonates has been reported (Fried and Makin, 1987).”
Background
Cited by
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509
Batalla, A., Bhattacharyya, S., Yücel, M., Fusar-Poli, P., Crippa, J. A., Nogué, S., Torrens, M., Pujol, J., Farré, M., & Martin-Santos, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055821 · Cited by 416
Degenhardt, L., Coffey, C., Romaniuk, H., Swift, W., Carlin, J. B., Hall, W. D., & Patton, G. C. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04015.x · Cited by 237
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
“A number of studies demonstrate a subtle rather than gross effect of cannabis upon later functioning, including the development of schizophreniform psychotic symptoms (for review, see Sundram 2006).”
BackgroundBidirectional cannabinoid modulation of social behavior in adolescent rats
Trezza, V., & Vanderschuren, L. J. M. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1025-3 · Cited by 159
“Second, exposure to exogenous cannabinoid drugs inhibits sociability, perhaps by disrupting cognitive functions necessary to perform adequate social interactions (Adolphs 2003; Egerton et al. 2006; Rushworth et al. 2007; Schneider and Koch 2002; Sundram 2006).”
Background
Metadata
- Authors
- Sundram, S.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 21
- Issue
- 4
- Pages
- 245-254
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2163620313
- Cited by
- 89
- References
- 15
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.